{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:23:45Z","timestamp":1794479025841,"version":"4.9.1"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Inhibition of the neonatal Fc receptor (FcRn) for IgG is a promising new therapeutic strategy for antibody\u2010mediated disorders. We report our real\u2010life experience with efgartigimod (EFG) in 19 patients with generalized myasthenia gravis (gMG) along a clinical follow\u2010up of 14\u2009months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>EFG was administered according to the GENERATIVE protocol (consisting of a Fixed period of two treatment cycles [given 1\u2009month apart] of four infusions at weekly intervals, followed by a Flexible period of re\u2010cycling in case of worsening). Eight patients were positive for acetylcholine receptor antibody, four for muscle\u2010specific tyrosine kinase antibody, and two for lipoprotein\u2010related protein 4 antibody, and five were classified as triple negative. Efficacy of EFG was assessed by the Myasthenia Gravis Activities of Daily Living, Myasthenia Gravis Composite, and Quantitative Myasthenia Gravis scales.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010three percent of patients needed three treatment cycles, 26% needed four, and 21% needed five along the 14\u2010month clinical follow\u2010up. Meaningful improvement was observed at the end of each cycle with the clinical scores adopted. EFG had a dramatic effect on disease course, as during the year before treatment eight of 19 patients (42%) were hospitalized, and 15 of 19 (79%) needed treatment with plasma exchange or immunoglobulins; three of 19 (16%) were admitted to the intensive care unit. During EFG, none of the patients was hospitalized and only one patient required plasma exchange and intravenous immunoglobulins. No major side effects or infusion\u2010related reactions occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We observed that EFG was safe and modified significantly the course of the disease along a 14\u2010month follow\u2010up. Our experience strengthens the role of FcRn inhibition as an effective new tool for long\u2010term treatment of gMG.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.16189","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T16:29:32Z","timestamp":1704212972000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Efgartigimod in generalized myasthenia gravis: A real\u2010life experience at a national reference center"],"prefix":"10.1111","volume":"31","author":[{"given":"Rita","family":"Frangiamore","sequence":"first","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiammetta","family":"Vanoli","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"},{"name":"Department of Human Neurosciences Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Andreetta","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Ciusani","sequence":"additional","affiliation":[{"name":"Laboratory of Neurological Biochemistry and Neuropharmacology Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-5173","authenticated-orcid":false,"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Gallone","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Colasuonno","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tramacere","sequence":"additional","affiliation":[{"name":"Department of Research and Clinical Development, Scientific Directorate Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cheli","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pinna","sequence":"additional","affiliation":[{"name":"argenx Italy  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-5737","authenticated-orcid":false,"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-5224","authenticated-orcid":false,"given":"Carlo","family":"Antozzi","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Neuromuscular Diseases Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"},{"name":"Immunotherapy and Apheresis Departmental Unit Fondazione IRCCS Istituto Neurologico C. Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00357-4"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00463-4"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827b907b"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1573-2"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13549"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00981"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S377056"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3"},{"issue":"55","key":"e_1_2_10_19_1","first-page":"16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America","volume":"12","author":"Jaretzki A","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163988.28892.79"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.2393"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2020-0145"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2022.2104261"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11517-w"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22002"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.12.003"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27974"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.16189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T09:37:03Z","timestamp":1710754623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.16189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/ene.16189"],"URL":"https:\/\/doi.org\/10.1111\/ene.16189","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"2023-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e16189"}}